GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Eupraxia Pharmaceuticals Inc (TSX:EPRX) » Definitions » Total Assets

Eupraxia Pharmaceuticals (TSX:EPRX) Total Assets : C$49.59 Mil (As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Eupraxia Pharmaceuticals Total Assets?

Eupraxia Pharmaceuticals's Total Assets for the quarter that ended in Mar. 2024 was C$49.59 Mil.

During the past 3 years, the average Total Assets Growth Rate was -1.80% per year. During the past 5 years, the average Total Assets Growth Rate was -11.70% per year.

During the past 7 years, Eupraxia Pharmaceuticals's highest 3-Year average Total Assets Growth Rate was -1.80%. The lowest was -18.40%. And the median was -12.50%.

Total Assets is connected with ROA %. Eupraxia Pharmaceuticals's annualized ROA % for the quarter that ended in Mar. 2024 was -85.23%. Total Assets is also linked to Revenue through Asset Turnover. Eupraxia Pharmaceuticals's Asset Turnover for the quarter that ended in Mar. 2024 was 0.00.

Eupraxia Pharmaceuticals Total Assets Historical Data

The historical data trend for Eupraxia Pharmaceuticals's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Eupraxia Pharmaceuticals Total Assets Chart

Eupraxia Pharmaceuticals Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Total Assets
Get a 7-Day Free Trial 3.31 1.46 31.35 25.98 27.19

Eupraxia Pharmaceuticals Quarterly Data
Dec18 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Total Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 20.40 34.19 27.19 49.59

Eupraxia Pharmaceuticals Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Eupraxia Pharmaceuticals's Total Assets for the fiscal year that ended in Dec. 2023 is calculated as

Total Assets=Total Equity (A: Dec. 2023 )+Total Liabilities (A: Dec. 2023 )
=1.197+25.992
=27.19

Eupraxia Pharmaceuticals's Total Assets for the quarter that ended in Mar. 2024 is calculated as

Total Assets=Total Equity (Q: Mar. 2024 )+Total Liabilities (Q: Mar. 2024 )
=24.51+25.081
=49.59

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Eupraxia Pharmaceuticals  (TSX:EPRX) Total Assets Explanation

Total Assets is connected with ROA %.

Eupraxia Pharmaceuticals's annualized ROA % for the quarter that ended in Mar. 2024 is

ROA %=Net Income (Q: Mar. 2024 )/( (Total Assets (Q: Dec. 2023 )+Total Assets (Q: Mar. 2024 ))/ count )
=-32.72/( (27.189+49.59)/ 2 )
=-32.72/38.3895
=-85.23 %

Note: The Net Income data used here is four times the quarterly (Mar. 2024) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Eupraxia Pharmaceuticals's Asset Turnover for the quarter that ended in Mar. 2024 is

Asset Turnover
=Revenue (Q: Mar. 2024 )/( (Total Assets (Q: Dec. 2023 )+Total Assets (Q: Mar. 2024 ))/ count )
=0/( (27.189+49.59)/ 2 )
=0/38.3895
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Eupraxia Pharmaceuticals Total Assets Related Terms

Thank you for viewing the detailed overview of Eupraxia Pharmaceuticals's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Eupraxia Pharmaceuticals (TSX:EPRX) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Eupraxia Pharmaceuticals Inc (TSX:EPRX) » Definitions » Total Assets
Comparable Companies
NEOE:MMED XCNQ:DTC TSXV:NGEN TSX:ONC TSX:BCT XCNQ:MSET TSXV:ARCH TSXV:MIR TSXV:DMT TSX:HBP OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
EPRXF:USA
Address
201-2067 Cadboro Bay Road, Victoria, BC, CAN, V8R 5G4
Website
https://www.eupraxiapharma.com
Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to existing pharmaceuticals. Its product EP-104 is used for the treatment of osteoarthritis and eosinophilic esophagitis symptoms.
Executives
James Allen Helliwell Director